L & L Bio Co., Ltd., Ningbo, China
Clinical trials sponsored by L & L Bio Co., Ltd., Ningbo, China, explained in plain language.
-
Scientists test novel Two-Pronged attack on tough cancers
Disease control Recruiting nowThis study is testing a new combination of two experimental drugs, LB1410 and LB4330, for people with advanced solid tumors that have spread or cannot be treated with standard therapies. The main goals are to find a safe and effective dose and to see if the combination can shrink…
Phase: PHASE1, PHASE2 • Sponsor: L & L Bio Co., Ltd., Ningbo, China • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
New Double-Action drug enters human testing for Tough-to-Treat cancers
Disease control Recruiting nowThis is a first-in-human, early-stage study to check the safety and find the right dose of an experimental drug called LB1410. The drug is designed to help the immune system fight cancer by blocking two different targets (PD-1 and TIM-3) at once. It will be given by IV to about 1…
Phase: PHASE1 • Sponsor: L & L Bio Co., Ltd., Ningbo, China • Aim: Disease control
Last updated Feb 25, 2026 15:08 UTC